TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.
Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D, Kline JP, Racil Z, Galluzzi L, Spisek R, Fucikova J.
Rakova J, et al. Among authors: salek c.
Oncoimmunology. 2021 Mar 8;10(1):1889822. doi: 10.1080/2162402X.2021.1889822.
Oncoimmunology. 2021.
PMID: 33758676
Free PMC article.